Pharmaceutical and Life Sciences
An environment of relentless challenge and change is the norm for pharmaceutical and life sciences companies. Despite critical need and high demand for its products, the industry remains under pressure from physicians, patients, payers and regulators to deliver more effective treatments at lower cost. Its current business model, based on development and marketing of blockbuster drugs, is increasingly economically unsustainable and operationally unsuited to the kind of quick action needed to meet complex stakeholder demands.
Growth opportunities inherent in change
Yet the future holds promise:
- The ramp-up of personalized medicine and increasing number of biologic products in development portend growth for the industry.
- Delivery of targeted, specialty medicines to selected groups of patients should improve outcomes and boost profitability.
- Rising populations and personal incomes in emerging markets have the potential to broaden the customer base in untapped and underserved regions.
Industry transformation inevitable
To seize these opportunities, the industry must embrace a fundamentally new approach to doing business. It must adopt transformational business models that rely on diversification and collaboration with healthcare payers, providers and nontraditional partners. The goal: to deliver bundled product-service packages of patient-centered, outcomes-based care.
We know the challenges you face in today's marketplace
Explore the challenges that we hear about every day. See what services and solutions PwC has to offer.
Our latest thinking for pharmaceuticals and life sciences
- Medtech Focus: IRS and Treasury publish notice of proposed rulemaking implementing new Medical Device Excise Tax
-
Medtech Focus: IRS and Treasury publish notice of proposed rulemaking implementing new Medical Device Excise Tax
On February 3, 2012, the IRS and Treasury issued a Notice of Proposed Rulemaking and Notice of Public Hearing ("NPRM") concerning Taxable Medical Devices pursuant to the new I.R.C. § 4191 federal manufacturers excise tax on medical devices. This Medtech Focus piece is a supplement to the Medical Device Tax Alert issued on 3 February 2012 and includes detailed analysis and insights into the regulations.
- California Biomedical Industry, 2012 Report
-
California Biomedical Industry, 2012 Report
The California biomedical industry report is a joint effort between California Health Institute (CHI), BayBio and PwC. It presents a portrait of California's biomedical industry at the beginning of 2012 and includes data on employment, wages, education and investment, as well as a snapshot of the product development pipeline.
- MoneyTree: Zigzagging upward
-
MoneyTree: Zigzagging upward
Life sciences venture funding jumps 21% in 2011 but quarterly performance falls short.
- Owning the disease: A new transformational business model for healthcare
-
Owning the disease: A new transformational business model for healthcare
To survive the coming storm, biomedical companies must build new models of innovation that are anchored in consumer-centric disease solutions rather than the traditional R&D department approaches.
- Sunshine Act Proposed Regulations
-
Sunshine Act Proposed Regulations
On December 14, 2011, the Centers for Medicare & Medicaid Services (CMS) published a proposed rule providing details for implementing the Physician Payment Sunshine Act (Sunshine Act) provisions under the Patient Protection and Affordable Care Act.
- Medtech focus: Social media
-
Medtech focus: Social media
Companies that rely on innovation cannot afford to omit social media for sales and marketing, product development, and business relationships from their business strategy. This alert provides company examples, basic guidance on developing a well-planned, systematic approach, and the overall opportunities offered to medical technology companies considering participating in social media.
- Diagnostics 2011: M&A surges, companion diagnostics accelerate, and early detection offers new prospects
-
Diagnostics 2011: M&A surges, companion diagnostics accelerate, and early detection offers new prospects
This report shares an overview of M&A deal activity during the past two years and the factors driving it, the development of new prospects for early detection testing and a review of significant events for the development of personalized medicine.
- Aspiring giants: How small pharmas can drive to $1 billion — and beyond
-
Aspiring giants: How small pharmas can drive to $1 billion — and beyond
Amid the volatile blend of opportunity and challenge in the global pharmaceutical industry, only a few small companies have exceeded the $1 billion revenue mark over the past two decades. PwC's report studies thirty companies that catapulted themselves beyond the $1 billion revenue mark, and the three winning strategies they pursued to jump-start that growth.
- Top health industry issues of 2012
-
Top health industry issues of 2012
This year's report provides more insight into the following trends: the impact of higher deductibles, how providers and insurers are teaming up for population health, potential drug shortages, health informatics, privacy and security, health insurance exchanges, pharma industry adapts to a post-blockbuster business model, social media in health, how politics may influence policy.
- MoneyTree: Reaching for growth
-
MoneyTree: Reaching for growth
Life sciences venture capital falls short of strong second-quarter performance, but year-over-year trend remains positive.
- Report: Pharma 2020: Supplying the future
-
Report: Pharma 2020: Supplying the future
Many pharmaceutical firms are trying to discover, develop and market medicines more efficiently, but they've invested relatively little effort in reconfiguring their manufacturing and distribution operations. Yet the supply chain is just as important; it's the link between the laboratory and the marketplace.
- Medical Technology Innovation Scorecard
-
Medical Technology Innovation Scorecard
PwC's Medical Technology Innovation Scorecard: The race for global leadership assesses nine countries' capacity and capability for medical technology innovation: Brazil, China, France, Germany, India, Israel, Japan, United Kingdom, United States.
- Health Reform: Prospering in a post-reform world
-
Health Reform: Prospering in a post-reform world
This PricewaterhouseCoopers' Health Research Institute report illustrates the mega trends that health executives will face as a result of health reform and provides recommendations on prospering in the post-reform world.
12:00 - 1:00pm ET
- Michael Swanick
- US Pharmaceuticals and Life Sciences Tax Leader
- Tel: +1 (267) 330 6060
- James Connolly
- US Pharmaceuticals and Life Sciences Assurance Leader
- Tel: +1 (617) 530 6213
- Douglas Strang
- US Pharmaceuticals and Life Sciences Advisory Leader
- Tel: +1 (267) 330 3045
